Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Anthera Pharmaceuticals, Inc. (ANTH) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Anthera Pharmaceuticals is a biopharmaceutical company engaged in developing and commercializing products for the treatment of serious illnesses, such as cardiovascular and autoimmune diseases. The company’s clinical-stage program includes a Phase 2 study of blisibimod, which targets elevated B-lymphocyte stimulator (BLyS or BAFF) levels and has been associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. For more information, visit the company’s Web site at www.anthera.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below:

This entry was posted in BIO Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *